Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
RESEARCH TOOLSreports
Holding KZIA?
Track your performance easily
KZIA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.19 - $1.58
Previous Close$0.33
Volume208.90K
Average Volume (3M)13.32M
Market Cap
$9.83M
Enterprise Value$6.39M
Total Cash (Recent Filing)AU$5.24M
Total Debt (Recent Filing)AU$1.80M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Feb 19, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jan 28, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding29,790,000
10 Day Avg. Volume2,674,898
30 Day Avg. Volume13,321,825
Standard Deviation0.30
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside515.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Kazia Therapeutics News
PremiumCompany Announcements
Kazia Therapeutics Advances Cancer Treatment Options
PremiumCompany Announcements
Kazia’s Paxalisib Shows Potential in Glioblastoma Trial
PremiumCompany Announcements
Kazia Therapeutics Announces Executive Changes
Ownership Overview
1.30%
Insiders
0.02% Mutual Funds
0.13% Other Institutional Investors
98.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $0.19 and its highest was $1.58 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Currently, no data Available
When is Kazia Therapeutics Limited’s upcoming earnings report date?
Kazia Therapeutics Limited’s upcoming earnings report date is Feb 19, 2025 which is in 152 days.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited pays a Notavailable dividend of $15.65 which represents an annual dividend yield of N/A. See more information on Kazia Therapeutics Limited dividends here
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 29,769,165 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Among the largest hedge funds holding Kazia Therapeutics Limited’s share is Platinum Investment Management. It holds Kazia Therapeutics Limited’s shares valued at N/A.
---
Kazia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (515.95% Upside)
$2.00 (515.95% Upside)
Blogger Sentiment
Bullish
KZIA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.26%
12-Months-Change
Fundamentals
Return on Equity
-181.74%
Trailing 12-Months
Asset Growth
-11.86%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
---
KZIA Stock 12 Month Forecast
Average Price Target
$2.00
▲(515.95% Upside)
Technical Analysis
Best Analysts Covering KZIA
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-47.93%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.93% per trade.
---